2024年11月12日,礼来中国宣布其1类新药穆优达®(奥氟格列隆钙片)获国家药监局批准上市 1。作为国内首个获批用于成人体重管理的口服小分子非肽类胰高血糖素样肽-1(GLP-1)受体激动剂,该药物适用于在控制饮食和增加运动基础上,仍肥胖或超重并伴有至少一种体重相关合并症的成人 1。
临床数据显示,在ATTAIN-1研究中,患者持续72周接受最高剂量治疗后,平均体重下降12.4千克,约40%的患者减重超过15% 1。此外,该药可使内脏脂肪减少超30%,腰围最大缩减约11厘米 1。安全性方面,不良事件以轻中度胃肠道反应为主,未观察到肝脏安全性信号 1。
该药无需冷链运输和贮存,可在室温下保存 1。未来,穆优达®将在北京经开区实现规模化生产 1。目前,针对成人2型糖尿病适应症的中国上市申请已进入审批阶段 1。
Eli Lilly China announced on November 12 that the National Medical Products Administration has approved its oral GLP-1 receptor agonist, Muiyouda® (orforglipron calcium tablets), for market launch 1. This approval marks the introduction of the first Class 1 new drug and oral small-molecule non-peptide GLP-1 receptor agonist authorized in China for adult weight management 1. The medication is intended for adults who remain obese or overweight with at least one weight-related comorbidity, despite efforts to control diet and increase physical activity 1.
Clinical data from the ATTAIN-1 study demonstrates significant efficacy, showing an average weight reduction of 12.4 kilograms after 72 weeks of treatment at the highest dose 1. Approximately 40% of patients experienced weight loss exceeding 15%, while visceral fat decreased by more than 30% and waist circumference was reduced by up to 11 centimeters 1. Regarding safety, adverse events were primarily mild to moderate gastrointestinal reactions, with no observed signals of liver toxicity 1.
The drug will be manufactured at scale in the Beijing Economic-Technological Development Area 1. Unlike many other treatments, it does not require cold chain transportation or storage and can be kept at room temperature, which is expected to improve patient compliance and alleviate pressure on top-tier hospitals 1. Additionally, the application for approval of orforglipron for treating adult type 2 diabetes in China has already entered the review stage 1.
评论
还没有评论,欢迎留下第一条。